Clinical trials: Resectable Lung Non-Small Cell Carcinoma
Non-small Cell Lung Cancer Stage III
Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer
This is a phase II, single-arm, open-label study to evaluate the efficacy and safety of the third generation tyrosine kinase inhibitors (TKIs) Almonertinib (HS-10296) as neoadjuvant and adjuvant therapy for potential resectable…
- Trial name
- NCT04685070
- Testing
- HS-10296 (Almonertinib)
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Non-Small Cell Lung Cancer
Neoadjuvant Ensartinib in ALK Positive Resectable Stage II to III Non-Small Cell Lung Cancer
This single-arm, prospective, multicenter, phase II study is designed to evaluate the efficacy and safety of ensartinib as neoadjuvant treatment in ALK positive, resectable for stage II to III non-small cell lung cancer patients.
- Trial name
- NCT06779539
- Testing
- Ensartinib
- Volunteers
- 33 people
- Sponsor
- West China Hospital
Resectable Non-small Cell Lung Cancer
A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC
This clinical trial aims to evaluate the efficacy and safety of neoadjuvant therapy with Limertinib Followed by Sintilimab and Chemotherapy in resectable Stage II-IIIB EGFR-Mutant NSCLC.
- Trial name
- NEO-LISI (NCT07038460)
- Testing
- Limertinib+sintilimab+chemotherapy, Limertinib+chemotherapy, surgery
- Where
- 6 sites in China
- Volunteers
- 134 people
- Sponsor
- Wen-zhao ZHONG
Non-small Cell Lung Cancer
Real-world Treatment Patterns and Associated Outcomes in Patients With Resectable Early-stage Non-small Cell Lung Cancer
This is a non-interventional, multi-country, multicentre, retrospective study designed to determine the treatment patterns and associated survival rate in patients with primary stage IA to IIIB resectable NSCLC diagnosed between…
- Trial name
- THASSOS-INTL (NCT04808050)
- Where
- 25 sites in Australia, Egypt and 5 more
- Volunteers
- 748 people
- Sponsor
- AstraZeneca
Non-small-cell Lung Cancer (NSCLC)
Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable NSCLC
Explorative study, which evaluates the effect of Camrelizumab combined with albumin-bound paclitaxel and platinum in neoadjuvant treatment of resectable non-small-cell lung carcinoma.
- Trial name
- NCT04338620
- Testing
- camrelizumab、albumin-bound paclitaxel and platinum, albumin-bound paclitaxel and platinum
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Tang-Du Hospital
Non Small Cell Lung Cancer
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
ADOPT-lung is an international, multicentre, open-label randomised phase III trial. Protocol treatment consists of 3-4 cycles of neoadjuvant durvalumab in combination with platinum-based doublet chemotherapy, followed by surgery.
- Trial name
- ADOPT-lung (NCT06284317)
- Testing
- Adjuvant durvalumab
- Where
- 42 sites in Australia, Austria and 8 more
- Volunteers
- 290 people
- Sponsor
- ETOP IBCSG Partners Foundation
NSCLC (Non-small Cell Lung Cancer), Neoadjuvant Immunotherapy
A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC
The goal of this clinical trial is to learn if tislelizumab in combination with anlotinib and platinum-based doublet chemotherapy works to treat for resectable stage II-IIIB driver gene-negative NSCLC.
- Conditions
- NSCLC (Non-small Cell Lung Cancer), Neoadjuvant Immunotherapy, Adjuvant Immunotherapy
- Trial name
- NCT06977828
- Testing
- tislelizumab in combination with anlotinib and platinum-based doublet chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Non Small Cell Lung Cancer
Customized Neoadjuvant Versus Standard Chemotherapy in NSCL Patients With Resectable Stage IIIA (N2)Disease
The investigators hypothesized that NSCL patients receiving therapy based on their baseline tumor markers levels would attain higher response rates than patients in the control arm receiving non customized therapy.
- Trial name
- CONTEST (NCT01784549)
- Testing
- Cisplatin Docetaxel Gefitinib Pemetrexed Vinorelbine Gemcitabine
- Where
- Italy
- Volunteers
- 168 people
- Sponsor
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Non-Small Cell Lung Cancer - Completely Resectable
DNP-Modified Autologous Tumor Cell Vaccine for Resectable Non-Small Cell Lung Cancer
To determine if a vaccine made from patient's own tumor tissue can stimulate an immune response against the patient's tumor cells. To determine the safety of the vaccine
- Trial name
- NCT00298298
- Testing
- L-Vax: Autologous, DNP-Modified NSCLC Vaccine
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- AVAX Technologies
Resectable Non-Small-Cell Lung Cancer
Propranolol Hydrochloride Combined With Toripalimab and Platinum-based Chemotherapy in Resectable Non-Small Cell Lung Cancer
This is a prospective, multicenter, open-label study designed to evaluate the safety and tolerability of propranolol hydrochloride in combination with toripalimab and platinum-based chemotherapy as perioperative treatment in…
- Trial name
- NeoBRIO (NCT07886229)
- Testing
- Propranolol Hydrochloride, Toripalimab, Chemotherapy
- Where
- 4 sites in China
- Volunteers
- 9 people
- Sponsor
- Second Xiangya Hospital of Central South University
Non-Small-Cell Lung
A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)
This is a randomized, double-blinded study designed to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of neoadjuvant treatment with atezolizumab (MPDL3280A) or placebo in combination with platinum-based…
- Trial name
- NCT03456063
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Nab-paclitaxel, Pemetrexed
- Where
- 117 sites in United States, Australia and 22 more
- Volunteers
- 453 people
- Sponsor
- Hoffmann-La Roche
Resectable Stage II-IIIa NSCLC
Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC
This is a randomized, open-label, multi-center Phase III clinical study aimed at head-to-head evaluating the clinical efficacy of three immunotherapy strategies, namely perioperative immunotherapy, neoadjuvant immunotherapy, and…
- Trial name
- ECTOP-1030 (NCT07554846)
- Testing
- Peroperative immunotherapy, Neoadjuvant immunotherapy, Adjuvant immunotherapy
- Where
- China
- Volunteers
- 759 people
- Sponsor
- Fudan University
High-Risk Resectable NSCLC
ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer
The proposed study will evaluate the safety and feasibility of preoperative administration nivolumab in patients with high-risk resectable NSCLC, and will facilitate a comprehensive exploratory characterization of the tumor…
- Trial name
- NCT03732664
- Testing
- Nivolumab, Pembrolizumab, Toripalimab, Sintilimab, Sintilimab, Tislelizumab, Durvalumab
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Non Small Cell Lung Cancer
Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC
The primary aim of this single arm, phase II study is to determine the efficacy of the combination therapy Pembrolizumab/Lenvatinib regarding the rate of major pathological response (MPR-Rate).
- Trial name
- INNWOP1 (NCT04875585)
- Testing
- neoadjuvant therapy with Pembrolizumab/Lenvatinib, Surgery, Adjuvant Treatment Phase
- Where
- Austria
- Volunteers
- 33 people
- Sponsor
- Medical University Innsbruck
Lung Neoplasm Malignant
Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer
Neoadjuvant chemotherapy followed by surgery has been recommended as the standard treatment for locally advanced and resectable non-small cell lung cancer (NSCLC). However, its efficacy remains to be improved.
- Trial name
- NCT04973293
- Testing
- sintilimab, bevacizumab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ruijin Hospital
Potentially Resectable MET-altered Non-Small Cell Lung Cancer
Vebreltinib for Neoadjuvant in MET-altered Stage IIIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)
According to the 2024 edition of the NCCN guidelines and the 2023 edition of the CSCO guidelines, perioperative treatment is recommended for patients with stage IIIA and IIIB (T3N2) non-small cell lung cancer (NSCLC).
- Trial name
- NCT06644313
- Testing
- Vebreltinib
- Volunteers
- 31 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Lung Cancer
Detection of Minimal Residual Disease in Resectable Stage II-IIIB Non-small Cell Lung Cancer
Predicting relapse and overall survival in potentially resectable Stage IIIA-IIIB Non-small Cell Lung Cancer (NSCLC) patients remains challenging.
- Trial name
- NCT06267144
- Testing
- Sintilimab plus chemotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Hospital of Jilin University
Non Small Cell Lung Cancer, EGFR Gene Mutation
Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.
This is a single-center, prospective, single-arm, phase II study of Osimertinib combined with Aspirin neoadjuvant therapy for resectable, EGFR mutated non-small cell lung cancer (NSCLC).
- Trial name
- NCT06018688
- Testing
- Osimertinib, Aspirin
- Volunteers
- 44 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Unresectable Stage III Non-small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)
IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer
This study is a single-arm, phase II clinical trial evaluating the safety and efficacy of IBI363 combined with chemotherapy as a neoadjuvant treatment of non-small cell lung cancer.
- Trial name
- NCT07408635
- Testing
- IBI363 + Chemotherapy
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Non-small Cell Lung Cancer
Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer
This is a prospective, single-arm, multi-center, phase II clinical study to evaluate the efficacy and safety of Envafolimab injection (PD-L1) combined with Disitamab Vedotin (HER2 ADC) and Carboplatin for resectable, HER2-Mutant…
- Trial name
- neovision (NCT06734182)
- Testing
- Envafolimab injections+intravenous Disitamab Vedotin+carboplatin
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Guangdong Provincial People's Hospital